Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin's lymphoma treated with the UKCCSG 9003/9002 protocols
Article first published online: 20 DEC 2001
British Journal of Haematology
Volume 112, Issue 4, pages 965–968, March 2001
How to Cite
Atra, A., Gerrard, M., Hobson, R., Imeson, J. D., Hann, I. M. and Pinkerton, C. R. (2001), Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin's lymphoma treated with the UKCCSG 9003/9002 protocols. British Journal of Haematology, 112: 965–968. doi: 10.1046/j.1365-2141.2001.02647.x
- Issue published online: 20 DEC 2001
- Article first published online: 20 DEC 2001
- Received 6 October 2000; accepted for publication 16 November 2000
- B-acute lymphoblastic leukaemia;
- B-non-Hodgkin's lymphoma.
Twenty-six children with B-cell acute lymphoblastic leukaemia (B-ALL) or Murphy Stage III or IV B-cell non-Hodgkin's lymphoma (B-NHL) progressed or relapsed after first-line therapy with a short, intensive multiagent chemotherapy regimen [United Kingdom Childhood Cancer Study Group (UKCCSG) 9003] (n = 62) or a slightly less intensive regimen (UKCCSG 9002) (n = 112). Eight patients (4·6%) never achieved complete remission (CR) and 18 (10·3%) relapsed. Second-line therapy resulted in remission for eight patients (30%). All patients initially treated with the 9003 protocol died. Three patients (11·5%) in the 9002 group, including one who never achieved CR in the primary site, are alive after second-line therapy. This study confirms that the prognosis of relapsed or refractory B-ALL/B-NHL is poor and exceptionally so if relapse occurred less than 6 months from diagnosis. High-dose therapy with stem cell rescue was used in only seven patients; its role needs to be studied further.